



Supplementary Figure 1A. Recombinant RHA is homogenously purified. The purified RHA was loaded to Gel Filtration column containing HiLoad 26/600 Superdex200pg (320 ml) matrix. The sharpness and symetric distribution of the both sides of 280 nm peak demonstrated that purified RHA fractions were homogenously.




Supplementary Figure 1B: Negative controls for RHA dependent helicase activity. i. Without RHA or with Heat Inactivated (H.I) RHA or without ATP or without MgCl₂ strand separation of dsRNA cannot happen. ii. Non-helicase protein, Ezrin, cannot drive helicase reaction.


i




ii




iii



Supplementary Figure 1C. RHA utilizes i.CTP, ii.UTP and iii. GTP in addition to ATP to drive helicase reaction.



Supplementary Figure S2: A. Coomassie blue stained gel showed the recombinant EWS-FLI1 after purification. B. In two minute reaction, recombinant EWS-FLI1 facilitates the annealing activity of RHA in a dose dependent manner. 10 nM EWS-FLI1 increased the annealing activity of RHA by four fold in 2 minutes. 10 nM EWS-FLI1, alone, facilitated the annealing of ssRNA significantly in 2 minutes. C. EWS-FLI1 did not inhibit the ATPase activity of RHA. A fluorescent substrate was used to measure the ATPase activity of 2 nM RHA and 2 nM RNA (black line) and 2 nM RHA with 2 nM EWS-FLI1 and 2 nM RNA (red line). The reactions without RNA, such as RHA (cayenne line), EWS-FLI1 and RHA (maroon line), EWS-FLI1 alone (green line) and EWS-FLI1 buffer with RHA (gray line) did not have ATPase activity.



Supplementary Figure 3: Increased salt decreased RNA binding affinity of EWS-FLI1. The RNA binding of EWS-FLI1 was measured in the 140 and 210 mM NaCl containing binding reactions. EWS-FLI1 protein concentration ranged from 0.1 to 312 nM by 5 fold. Free and protein bound RNA was resolved by 6% native PAGE.

www.bioinfo.ggc.org/cgi-bin/bindn/bindn.pl

```

Sequence:  MASTDYSTYSQAAAQQGYSAYTAQPTQGYAQTQAYGQQSYGTYGQPTDVSYTQAQTTY
Prediction:  ---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  665226655273435427636626256283666728256582784325564667276777

Sequence:  GQTAYATSYGQPPTGYTTPTAPQAYSQPVQGYGTGAYDTTATVTTTQASYAAQSAYGTQ
Prediction:  +++-+-+-----+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  567282678586784866562674755546443722526662746665567436637366

Sequence:  PAYPAYGQQPAATAPTRPQDGNKPTETSQPQSSTGGYNQPSLGYGQSNYSYPQVPGSYPM
Prediction:  ---+---+---+-----+---+---+---+---+---+---+---+---+---+---+
Confidence:  337246525244857796887786787897888976765553582878667364235443

Sequence:  QPVTAPPSYPPTSYSSTQPTSVDQSSYSQQNTYGPSSYGGQSSYGGQSSYGGQPPPTSYP
Prediction:  +---+-----+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  4475454786787888989677758677797778587789698778698788298668886

Sequence:  PTGSYSQAPSQYSQQSSSYGQQPSYDSVRRGAWGNMNSGLNKSPPLGCAQTISKNTQR
Prediction:  +-----+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  884788847778788778879756755588236264457625852225246726887688


Sequence:  PQPDPYQILGPTSSRLANPGSQIQLWQFLLELLSDSANASCITWEGTNGEFKMTDPDEV
Prediction:  ++-----+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  46233357533567925824726529779999936252324723365255456377434

Sequence:  ARRWGERKSKPNMNYDKLSRALRYYYDKNIMTKVHCRRYAYKDFHGIQAALQPHPTSS
Prediction:  +-----+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  476768987978455456583386238527547452887466878689937624235556

Sequence:  MYKYPSDISYMPHYHAHQKVNFPVPPHSSMPVTSSSFFGAASQYWTSPGGIYPNPVNP
Prediction:  -+-+---+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  266234374553265362358347364367252565253245525525264236322532

Sequence:  RHPNTHVPSHLGSYY
Prediction:  +-----+---+---+---+---+---+---+---+---+---+---+---+
Confidence:  824565625444523
    
```

Supplementary Figure 4: The RNA binding site prediction results for EWS-FLI1. A. The prediction result of catRAPID (<http://service.tartagialab.com/>), B. The prediction result of RNABindR (einstein.cs.iastate.edu/RNABindR) C. The prediction result of BindN ([//bioinfo.ggc.org/cgi-bin/bindn/bindn.pl](http://bioinfo.ggc.org/cgi-bin/bindn/bindn.pl)). The boxed regions in all three prediction results show the ets-binding domain of FLI1 protein.




wt Ets-DNA sequence

5'-ATG TAG ACC **GGA** AGT AAC TA-3'
 3'-TAC ATC TGG **CCT** TCA TTG AT-5'


mut Ets-DNA sequence

5'-ATG TAG ACC **GCT** AGT AAC TA-3'
 3'-TAC ATC TGG **CGA** TCA TTG AT-5'


Supplementary Figure 5: The RNA binding of EWS-FLI1 could be partially through the *ets*-DNA binding domain. Wild- type DNA containing GGAA (bold and underlined) or mutant GCTA sequences (bold and boxed) was included in the RNA binding assays of EWS-FLI1. 30 nM EWS-FLI1 was complexed with varying concentration from 0 to 3250 nM of the *ets*-DNA before the addition of dsRNA. The protein-RNA complexes were resolved with 6% native PAGE.




Supplementary Figure 6: YK-4-279 does not inhibit the helicase activity of RHA. 30 μ M YK-4-279 was added to helicase assay containing 1 nM RHA.




Supplementary Figure 7: RIP-seq determined overlapping transcripts from either EWS-FLI1 or RHA complexes. A. Gene Ontology term enrichment analysis of RNA found in both RHA and EWS-FLI1 protein complexes. B. The analysis of RNA continued to be overlapping from both RIP after YK-4-279 treatment. C. The GO analysis of RNA only present with EWS-FLI1 RIP after YK-4-279 treatment. D. GO term enrichment of RNA present in RHA-RIP following YK-4-279 treatment. E. GO enrichment analysis of RNA were no longer RIP by either protein after YK-4-279 treatment.



Supplementary Figure 8: YK-4-279 does not affect the RNA binding affinity of RHA or EWS-FLI1. A. RHA-RNA binding assay was carried out with the varying concentration of RHA in the presence of 30 μ M YK-4-279. RNA-protein complexes were resolved in 6% native PAGE. The affinities were calculated by using GraphPad. B. EWS-FLI1 and RNA binding assay was carried out with the varying concentration of EWS-FLI1 in the presence of 30 μ M YK-4-279. RNA-protein complexes were resolved in 6% native PAGE. The affinities were calculated by using GraphPad.



Supplementary Figure S9. Alignment of RHA and *S. cerevisiae* Prp43p sequences. The alignment generated by PHYRE indicates that the use of *S. cerevisiae* Prp43p as a template sequence allows not only for the reliable modeling of RHA's overall fold, but also for the modeling of conserved helicase motifs as described by Fairman-Williams et al. (2010). The query sequence belongs to RHA, the template sequence is Prp43p in the alignment.



Supplementary figure S10: A. Crystal structure of Prp43p (PDB code: 3KX2) shown in cartoon representation with marked helicase motifs as described by Fairman-Williams et al. (2010). The helicase motifs are those determined for RHA by Fairman-Williams and colleagues. B. Superposition of the Prp43p crystal structure (green) and modeled core fragment of RHA (blue). C. The model of RHA with marked helicase motifs.